Shingles Vaccine Shows Weaker Response in Systemic Sclerosis Patients But Remains Safe
SSc patients mount a lower antibody response to Shingrix than healthy controls, yet the vaccine triggers no disease flares — doctors still recommend it.
Summary
A prospective trial from Brazil found that patients with systemic sclerosis (SSc), an autoimmune connective tissue disease, produced significantly weaker antibody responses to the recombinant shingles vaccine Shingrix compared to healthy controls. Seroconversion rates were 92.6% in SSc patients versus 99.7% in controls, and antibody concentrations were roughly half those seen in controls. Importantly, the vaccine did not worsen SSc symptoms or trigger disease flares. Researchers concluded that while long-term protection may be reduced, the vaccine's strong safety profile means SSc patients should still receive it. Further studies are needed to determine how durable the immune protection actually is in this population.
Detailed Summary
For people living with systemic sclerosis, a chronic autoimmune disease that affects the skin and internal organs, vaccine effectiveness is not guaranteed. A new secondary analysis published in Rheumatology sheds light on how well the recombinant herpes zoster vaccine — Shingrix — actually works in this vulnerable population, and the findings raise important questions about long-term protection.
Researchers at the Universidade de Sao Paulo in Brazil analyzed data from 68 SSc patients and 299 healthy controls who received the standard two-dose Shingrix schedule. While 92.6% of SSc patients technically achieved seroconversion — defined as a fourfold increase in anti-glycoprotein E antibodies — this lagged behind the 99.7% rate seen in controls. More strikingly, the geometric mean antibody concentrations and factor increases in SSc patients were approximately half those observed in controls, suggesting that even patients who technically converted may carry weaker immune protection.
The good news is that safety was not a concern. SSc patients experienced no increase in disease flares, no worsening of symptoms, and adverse effects were comparable to or milder than controls, including fewer injection-site reactions. Cell-mediated immunity, another arm of immune defense, was not significantly reduced relative to healthy individuals.
The researchers attribute the blunted antibody response partly to the immune dysregulation inherent to SSc and partly to the immunosuppressant medications — such as mycophenolate mofetil — that many patients take. This mirrors patterns seen with other vaccines in autoimmune populations.
Practically, clinicians and SSc patients should not interpret these findings as a reason to skip vaccination. The authors explicitly support integrating Shingrix into SSc prevention protocols. However, this study underscores the need for long-term follow-up data to determine whether booster doses or alternative dosing strategies could improve durable protection in immunocompromised rheumatology patients.
Key Findings
- SSc patients had 92.6% seroconversion vs 99.7% in healthy controls after Shingrix vaccination.
- Antibody concentrations in SSc patients were roughly half those seen in healthy controls.
- No disease flares or worsening of SSc symptoms were observed post-vaccination.
- Cell-mediated immunity was not significantly diminished in SSc patients compared to controls.
- Researchers still recommend Shingrix for SSc patients due to its favorable safety profile.
Methodology
This is a news report summarizing a peer-reviewed secondary analysis published in the journal Rheumatology, based on a prospective randomized trial conducted in Brazil. The study included 68 SSc patients and 299 healthy controls, which is a relatively small patient sample but benefits from a prospective design and direct comparison group. Source credibility is high — MedPage Today is a reputable medical news outlet reporting on work from an established Brazilian academic medical center.
Study Limitations
The SSc patient sample was relatively small at 68 individuals, limiting statistical power for subgroup analyses. The study excluded patients on rituximab and cyclophosphamide, so findings may not apply to the full SSc population. Long-term follow-up data on actual shingles incidence in vaccinated SSc patients are not yet available, leaving the real-world protective efficacy uncertain.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.